Naito Yuji, Takagi Tomohisa
Human Immunology and Nutrition Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
J Clin Biochem Nutr. 2024 Nov;75(3):175-177. doi: 10.3164/jcbn.24-112. Epub 2024 Sep 6.
The role of the gut microbiota, especially bacterial flora, in the pathogenesis of inflammatory bowel disease (IBD) is becoming clearer. Advances in gut microbiota analysis and the use of gnotobiotics models have underscored the importance of gut bacteria and their metabolites in the progression of IBD. Fecal microbiota transplantation has shown promise in clinical trials for ulcerative colitis started as Advanced Medical Care B in Japan, raising expectations for its outcomes. This review explores the gut microbiota's role in IBD, encompassing both current knowledge and future prospects.
肠道微生物群,尤其是细菌菌群,在炎症性肠病(IBD)发病机制中的作用正变得越来越清晰。肠道微生物群分析和悉生生物学模型的应用进展突出了肠道细菌及其代谢产物在IBD进展中的重要性。粪便微生物群移植在日本作为高级医疗护理B启动的溃疡性结肠炎临床试验中已显示出前景,这提高了人们对其疗效的期望。本综述探讨了肠道微生物群在IBD中的作用,涵盖了当前的知识和未来的前景。